(R)-2-(Toluene-4-sulfonyloxymethyl)-6-methyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(Toluene-4-sulfonyloxymethyl)-6-methyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one
• 英文别名: [(2R)-6-methyl-8-oxo-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-2-yl]methyl 4-methylbenzenesulfonate
• 化学式: C₁₉H₁₉NO₆S
• 分子量: 389.429
• InChiKey: WLEAQISUXZNEHG-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  99.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-噻吩甲胺 、 (R)-2-(Toluene-4-sulfonyloxymethyl)-6-methyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one 、 富马酸 以 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 生成 2-{[(Thiophene-2-ylmethyl)-amino]-methyl}-6-methyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one
  参考文献：
  名称：

  Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino\x9b2 3-E!-indol-8-ones and

  摘要：

  式I的化合物：其中R.sup.1和R.sup.2分别是氢、烷基、苯基或苄基；或R.sup.1和R.sup.2一起是苄基亦可选择性地用如下定义的R.sup.3取代或烷基亦可选择性地用如下定义的R.sup.3取代，或R.sup.1和R.sup.2与它们附着的碳一起形成一个羰基或环烷基；R.sup.3是氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或双烷基氨基、烷酰胺基或烷磺酰胺基；R.sup.4是氢或烷基；m是整数0、1或2；n是整数0至6之间的整数；Z是氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环烷基、苯基亦可选择性地用如上定义的R.sup.3取代、苯氧基亦可选择性地用如上定义的R.sup.3取代、萘基亦可选择性地用如上定义的R.sup.3取代或萘氧基亦可选择性地用如上定义的R.sup.3取代、杂环芳基或杂环芳氧基，其中杂环芳基或杂环芳氧基的杂环环由噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色苷、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑组成，并且该杂环环可以选择性地用如上定义的R.sup.3取代；或者其药学上可接受的盐，用于治疗多巴胺系统疾病。

  公开号：

  US05756532A1

文献信息

• Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino-\x9b2,3-e!-indol-8-ones and
  申请人：American Home Products Corporation

  公开号：US05962465A1

  公开（公告）日：1999-10-05

  The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  化学式为I的化合物：##STR1## 其中R.sup.1和R.sup.2分别为氢、烷基、苯基或苄基；或R.sup.1和R.sup.2连在一起，是苄基亚甲基，可选地用下面定义的R.sup.3取代，或烷基亚甲基，或R.sup.1和R.sup.2与它们连接的碳形成羰基基团或环烷基；R.sup.3为氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或二烷基氨基、烷基酰胺或烷基磺酰胺；R.sup.4为氢或烷基；m为0、1或2的整数；n为0到6的整数，包括0和6；Z为氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环环烷基、苯基（可选地用上述定义的R.sup.3取代）、苯氧基（可选地用上述定义的R.sup.3取代）、萘基（可选地用上述定义的R.sup.3取代）或萘氧基（可选地用上述定义的R.sup.3取代）、杂环芳基或杂环芳基氧基，其中杂环芳基或杂环芳基氧基的杂环环选自噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色甘醇、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑，且杂环环可选地由上述定义的R.sup.3取代；或其药学上可接受的盐，适用于治疗多巴胺系统疾病。
• Dioxino derivatives and their use as dopamine agonists
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0771800A2

  公开（公告）日：1997-05-07

  The compounds of formula I: wherein R1 and R2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R1 and R2, taken together, are benzylidene optionally substituted with R3 as defined below or alkylidene, or R1 and R2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R3 as defined above, phenoxy optionally substituted with R3 as defined above, naphthyl optionally substituted with R3 as defined above or naphthyloxy optionally substituted with R3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  式 I 的化合物 其中 R1 和 R2 独立地为氢、烷基、苯基或苄基；或 R1 和 R2 合在一起为可选被下述定义的 R3 取代的亚苄基或亚烷基，或 R1 和 R2 与它们所连接的碳合在一起形成羰基或环烷基；R3 是氢、羟基、卤代、三氟甲基、三氟甲氧基、烷基、烷氧基、芳烷氧基、烷酰氧基、氨基、单或双烷基氨基、烷氨基或烷磺氨基； R4 是氢或烷基；m 是 0、1 或 2 的整数；n 是 0 至 6（包括 6）的整数；Z 是氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环烷基、任选被上 文定义的 R3 取代的苯基、任选被上文定义的 R3 取代的苯氧基、任选被上文定义的 R3 取代的萘基或任选被上文定义的 R3 取代的萘氧基、杂芳基或杂芳氧基、其中杂芳基或杂芳基氧基的杂环选自噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲哒唑、咪唑、铬烷、香豆素、羧基吡咯、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑，且该杂环任选被如上定义的 R3 所取代；或其药学上可接受的盐，可用于治疗多巴胺能系统疾病。
• Dioxino derivatives and their use as dopanine agonists
  申请人：Wyeth

  公开号：EP1375503A1

  公开（公告）日：2004-01-02

  The compounds of formula I: wherein R 1 and R2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R 1 and R2, taken together, are benzylidene optionally substituted with R3 as defined below or alkylidene, or R1 and R2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono-or di-alkylamino, alkanamido or alkanesulfonamido; R4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R3 as defined above, phenoxy optionally substituted with R3 as defined above, naphthyl optionally substituted with R3 as defined above or naphthyloxy optionally substituted with R3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  式 I 的化合物 其中 R1 和 R2 独立地为氢、烷基、苯基或苄基；或 R1 和 R2 合在一起为可选被下述定义的 R3 取代的亚苄基或亚烷基，或 R1 和 R2 与它们所连接的碳一起形成羰基或环烷基；R3 是氢、羟基、卤代、三氟甲基、三氟甲氧基、烷基、烷氧基、芳烷氧基、烷酰氧基、氨基、单或双烷基氨基、烷氨基或烷磺氨基； R4 是氢或烷基；m 是 0、1 或 2 的整数；n 是 0 至 6（包括 6）的整数；Z 是氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环烷基、任选被上 文定义的 R3 取代的苯基、任选被上文定义的 R3 取代的苯氧基、任选被上文定义的 R3 取代的萘基或任选被上文定义的 R3 取代的萘氧基、杂芳基或杂芳氧基、其中杂芳基或杂芳基氧基的杂环选自噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲哒唑、咪唑、铬烷、香豆素、羧基吡咯、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑，且该杂环任选被如上定义的 R3 所取代；或其药学上可接受的盐，可用于治疗多巴胺能系统疾病。
• US5756532A
  申请人：——

  公开号：US5756532A

  公开（公告）日：1998-05-26
• Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino\x9b2 3-E!-indol-8-ones and
  申请人：American Home Products Corporation

  公开号：US05756532A1

  公开（公告）日：1998-05-26

  The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  式I的化合物：其中R.sup.1和R.sup.2分别是氢、烷基、苯基或苄基；或R.sup.1和R.sup.2一起是苄基亦可选择性地用如下定义的R.sup.3取代或烷基亦可选择性地用如下定义的R.sup.3取代，或R.sup.1和R.sup.2与它们附着的碳一起形成一个羰基或环烷基；R.sup.3是氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或双烷基氨基、烷酰胺基或烷磺酰胺基；R.sup.4是氢或烷基；m是整数0、1或2；n是整数0至6之间的整数；Z是氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环烷基、苯基亦可选择性地用如上定义的R.sup.3取代、苯氧基亦可选择性地用如上定义的R.sup.3取代、萘基亦可选择性地用如上定义的R.sup.3取代或萘氧基亦可选择性地用如上定义的R.sup.3取代、杂环芳基或杂环芳氧基，其中杂环芳基或杂环芳氧基的杂环环由噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色苷、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑组成，并且该杂环环可以选择性地用如上定义的R.sup.3取代；或者其药学上可接受的盐，用于治疗多巴胺系统疾病。